NAC Lenvatinib plus Cisplatin

Phase II study of lenvatinib plus hepatic intra-arterial infusion chemotherapy with cisplatin in hepatocellular carcinoma paitents with high-risk of recurrence beyond the Milan criteria

Status

Recruiting

Phases

Phase 2

Study type

Interventional

Source

JPRN

Registry ID

JPRN-jRCT1041220110

Enrollment

Registered

2022-12-25

Start date

2023-01-12

Completion date

Unknown

Last updated

2026-06-29

For informational purposes only — not medical advice. Sourced from public registries and may not reflect the latest updates. Terms

Conditions

Hepatocellular carcinoma Hepatocellular carcinoma

Interventions

Lenvatinib plus hepatic intra-arterial infusion chemotherapy with cisplatin

lenvatinib, cisplatin

Eligibility

Sex/Gender

All

Inclusion criteria

Inclusion criteria: clinically diagnosed as hepatocellular carcinoma; Preserved liver functional reserve and scheduled for resection; diagnosed as high-risk hepatocellular carcinoma recurrence beyond the Milan criteria; 20 years or older; ECOG Performance status <=2; preservation of major organ function; written informed consent

Exclusion criteria

Exclusion criteria: refractory ascites or pleural effusion; risky varices; double cancer; metastases to central nervous system; severe complication; pregnant or lactating women, or women of childbearing potential; mental disorder; patients who investigator regards as inappropriate for candidate

Design outcomes

Primary

Measure	Time frame
Time to recurrence beyond the Milan criteria	—

Secondary

Measure	Time frame
progression-free survival, overall survival, objective response rate, tumor control rate, adverse events, liver functional reserve, subsequent therapies	—

Contacts

Public ContactTakeshi Terashima

Kanazawa University Hospital

tera@m-kanazawa.jp+81-76-265-2235

Outcome results

None listed

Source: JPRN (via WHO ICTRP) · Data processed: Jul 3, 2026